New molecules and adjuvants in the treatment of infections by Acinetobacter baumannii

References

• Tansarli GS, Karageorgopoulos DE, Kapaskelis A, et al. Impact of antimicrobial multidrug resistance on inpatient care cost: an evaluation of the evidence. Expert Rev Anti Infect Ther. 2013;11:321–331.
   PubMed Web of Science ®Google Scholar
• Chen CH, Lin LC, Chang YJ, et al. Infection control programs and antibiotic control programs to limit transmission of multi-drug resistant Acinetobacter baumannii infections: evolution of old problems and new challenges for institutes. Int J Environ Res Public Health. 2015;12:8871–8882.
   PubMed Web of Science ®Google Scholar
• Doi Y, Murray GL, Peleg AY. Acinetobacter baumannii: evolution of antimicrobial resistance-treatment options. Semin Respir Crit Care Med. 2015;36:85–98.
   PubMed Web of Science ®Google Scholar
• European Centre for Disease Prevention and Control. Antimicrobial resistance surveillance in Europe 2013. Stockholm: ECDC; 2014. [cited 2015 Oct 2]. Available from: http://ecdc.europa.eu/en/publications/_layouts/forms/Publication_DispForm.aspx?List=4f55ad51-4aed-4d32-b960-af70113dbb90&ID=1205
   Google Scholar
• Denys GA, Callister SM, Dowzicky MJ. Antimicrobial susceptibility among gram-negative isolates collected in the USA between 2005 and 2011 as part of the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.). Ann Clin Microbiol Antimicrob. 2013;12:24.
   PubMed Web of Science ®Google Scholar
• Molina J, Cordero E, Pachón J. New information about the polymyxin/colistin class of antibiotics. Expert Opin Pharmacother. 2009;10:2811–2828.
   PubMed Web of Science ®Google Scholar
• Fernández-Cuenca F, Tomás-Carmona M, Caballero-Moyano F, et al. In vitro activity of 18 antimicrobial agents against clinical isolates of Acinetobacter spp.: multicenter national study GEIH-REIPI-Ab 2010. Enferm Infecc Microbiol Clin. 2013;31:4–9.
   PubMed Web of Science ®Google Scholar
• Ko KS, Suh JY, Kwon KT, et al. High rates of resistance to colistin and polymyxin B in subgroups of Acinetobacter baumannii isolates from Korea. J Antimicrob Chemother. 2007;60:1163–1167.
   PubMed Web of Science ®Google Scholar
• Bialvaei AZ, Samadi Kafil H. Colistin, mechanisms and prevalence of resistance. Curr Med Res Opin. 2015;31:707–721.
   PubMed Web of Science ®Google Scholar
• Vila J, Pachón J. Therapeutic options for Acinetobacter baumannii infections: an update. Expert Opin Pharmacother. 2012;13:2319–2336.
   PubMed Web of Science ®Google Scholar
• Yan JJ, Jung JS, Lee JE, et al. Therapeutic effects of lysophosphatidylcholine in experimental sepsis. Nat Med. 2004;10:161–167.
   PubMed Web of Science ®Google Scholar
• Smani Y, Domínguez-Herrera J, Ibáñez-Martínez J, et al. Therapeutic efficacy of lysophosphatidylcholine in severe infections caused by Acinetobacter baumannii. Antimicrob Agents Chemother. 2015;59:3920–3924.
   PubMed Web of Science ®Google Scholar
• Mechkarska M, Prajeep M, Radosavljevic GD, et al. An analog of the host-defense peptide hymenochirin-1B with potent broad-spectrum activity against multidrug-resistant bacteria and immunomodulatory properties. Peptides. 2013;50:153–159.
   PubMed Web of Science ®Google Scholar
• Wang CQ, Yang CS, Yang Y, et al. An apolipoprotein E mimetic peptide with activities against multidrug-resistant bacteria and immunomodulatory effects. J Pept Sci. 2013;19:745–750.
   PubMed Web of Science ®Google Scholar
• Attoub S, Mechkarska M, Sonnevend A, et al. Esculentin-2CHa: a host-defense peptide with differential cytotoxicity against bacteria, erythrocytes and tumor cells. Peptides. 2013;39:95–102.
   PubMed Web of Science ®Google Scholar
• Zhao L, KuoLee R, Harris G, et al. c-di-GMP protects against intranasal Acinetobacter baumannii infection in mice by chemokine induction and enhanced neutrophil recruitment. Int Immunopharmacol. 2011;11:1378–1383.
   PubMed Web of Science ®Google Scholar
• Van Faassen H, KuoLee R, Harris G, et al. Neutrophils play an important role in host resistance to respiratory infection with Acinetobacter baumannii in mice. Infect Immun. 2007;75:5597–5608.
   PubMed Web of Science ®Google Scholar
• Ostorhazi E, Rozgonyi F, Szabo D, et al. Intramuscularly administered peptide A3-APO is effective against carbapenem-resistant Acinetobacter baumannii in mouse models of systemic infections. Biopolymers. 2011a;96:126–129.
   PubMed Web of Science ®Google Scholar
• Ostorhazi E, Rozgonyi F, Sztodola A, et al. Preclinical advantages of intramuscularly administered peptide A3-APO over existing therapies in Acinetobacter baumannii wound infections. J Antimicrob Chemother. 2010;65:2416–2422.
   PubMed Web of Science ®Google Scholar
• Ostorhazi E, Holub MC, Rozgonyi F, et al. Broad-spectrum antimicrobial efficacy of peptide A3-APO in mouse models of multidrug-resistant wound and lung infections cannot be explained by in vitro activity against the pathogens involved. Int J Antimicrob Agents. 2011b;37:480–484.
   PubMed Web of Science ®Google Scholar
• Maisetta G, Batoni G, Esin S, et al. In vitro bactericidal activity of human beta-defensin 3 against multidrug-resistant nosocomial strains. Antimicrob Agents Chemother. 2006;50:806–809.
   PubMed Web of Science ®Google Scholar
• Routsias JG, Karagounis P, Parvulesku G, et al. In vitro bactericidal activity of human beta-defensin 2 against nosocomial strains. Peptides. 2010;31:1654–1660.
   PubMed Web of Science ®Google Scholar
• Feng Z, Jia X, Adams MD, et al. Epithelial innate immune response to Acinetobacter baumannii challenge. Infect Immun. 2014;82:4458–4465.
   PubMed Web of Science ®Google Scholar
• Supp DM, Gardner J, Klingenberg JM, et al. Antibiotic resistance in clinical isolates of Acinetobacter baumannii, Pseudomonas aeruginosa, and Staphylococcus aureus does not impact sensitivity to human beta defensin 4. Burns. 2009;35:949–955.
   PubMed Web of Science ®Google Scholar
• García-Quintanilla M, Pulido MR, Moreno-Martínez P, et al. Activity of host antimicrobials against multidrug-resistant Acinetobacter baumannii acquiring colistin resistance through loss of lipopolysaccharide. Antimicrob Agents Chemother. 2014;58:2972–2975.
   PubMed Web of Science ®Google Scholar
• Feng X, Sambanthamoorthy K, Palys T, et al. The human antimicrobial peptide LL-37 and its fragments possess both antimicrobial and antibiofilm activities against multidrug-resistant Acinetobacter baumannii. Peptides. 2013;49:131–137.
   PubMed Web of Science ®Google Scholar
• Lin L, Tan B, Pantapalangkoor P, et al. Inhibition of LpxC protects mice from resistant Acinetobacter baumannii by modulating inflammation and enhancing phagocytosis. MBio. 2012;3:e00312–12.
   PubMed Web of Science ®Google Scholar
• Brown MF, Reilly U, Abramite JA, et al. Potent inhibitors of LpxC for the treatment of Gram-negative infections. J Med Chem. 2012;55:914–923.
   PubMed Web of Science ®Google Scholar
• Montgomery JI, Brown MF, Reilly U, et al. Pyridone methylsulfone hydroxamate LpxC inhibitors for the treatment of serious gram-negative infections. J Med Chem. 2012;55:1662–1670.
   PubMed Web of Science ®Google Scholar
• Tomaras AP, McPherson CJ, Kuhn M, et al. LpxC inhibitors as new antibacterial agents and tools for studying regulation of lipid A biosynthesis in Gram-negative pathogens. MBio. 2014;5:e01551–14.
   PubMed Web of Science ®Google Scholar
• Badger J, Chie-Leon B, Logan C, et al. Structure determination of LpxA from the lipopolysaccharide-synthesis pathway of Acinetobacter baumannii. Acta Crystallogr Sect F Struct Biol Cryst Commun. 2012;68:1477–1481.
   PubMedGoogle Scholar
• Badger J, Chie-Leon B, Logan C, et al. Structure determination of LpxD from the lipopolysaccharide-synthesis pathway of Acinetobacter baumannii. Acta Crystallogr Sect F Struct Biol Cryst Commun. 2013;69:6–9.
   PubMedGoogle Scholar
• de Leeuw EP. Efficacy of the small molecule inhibitor of Lipid II BAS00127538 against Acinetobacter baumannii. Drug Des Devel Ther. 2014;8:1061–1064.
   PubMed Web of Science ®Google Scholar
• Personne Y, Curtis MA, Wareham DW, et al. Activity of the type I signal peptidase inhibitor MD3 against multidrug-resistant Gram-negative bacteria alone and in combination with colistin. J Antimicrob Chemother. 2014;69:3236–3243.
   PubMed Web of Science ®Google Scholar
• Pollard JE, Snarr J, Chaudhary V, et al. In vitro evaluation of the potential for resistance development to ceragenin CSA-13. J Antimicrob Chemother. 2012;67:2665–2672.
   PubMed Web of Science ®Google Scholar
• Bozkurt-Guzel C, Savage PB, Akcali A, et al. Potential synergy activity of the novel ceragenin, CSA-13, against carbapenem-resistant Acinetobacter baumannii strains isolated from bacteremia patients. Biomed Res Int. 2014;2014:710273.
   PubMed Web of Science ®Google Scholar
• Vila-Farrés X, Callarisa AE, Gu X, et al. CSA-131, a ceragenin active against colistin-resistant Acinetobacter baumannii and Pseudomonas aeruginosa clinical isolates. Int J Antimicrob Agents. 2015;46:568–571.
   PubMed Web of Science ®Google Scholar
• Reffuveille F, de la Fuente-Núñez C, Mansour S, et al. A broad-spectrum antibiofilm peptide enhances antibiotic action against bacterial biofilms. Antimicrob Agents Chemother. 2014;58:5363–5371.
   PubMed Web of Science ®Google Scholar
• Gopal R, Kim YG, Lee JH, et al. Synergistic effects and antibiofilm properties of chimeric peptides against multidrug-resistant Acinetobacter baumannii strains. Antimicrob Agents Chemother. 2014;58:1622–1629.
   PubMed Web of Science ®Google Scholar
• Kaplan JB. Therapeutic potential of biofilm-dispersing enzymes. Int J Artif Organs. 2009;32:545–554.
   PubMed Web of Science ®Google Scholar
• Gawande PV, Leung KP, Madhyastha S. Antibiofilm and antimicrobial efficacy of DispersinB®-KSL-W peptide-based wound gel against chronic wound infection associated bacteria. Curr Microbiol. 2014;68:635–641.
   PubMed Web of Science ®Google Scholar
• Thompson RJ, Bobay BG, Stowe SD, et al. Identification of BfmR, a response regulator involved in biofilm development, as a target for a 2-aminoimidazole-based antibiofilm agent. Biochemistry. 2012;51:9776–9778.
   PubMed Web of Science ®Google Scholar
• de Léséleuc L, Harris G, KuoLee R, et al. In vitro and in vivo biological activities of iron chelators and gallium nitrate against Acinetobacter baumannii. Antimicrob Agents Chemother. 2012;56:5397–5400.
   PubMed Web of Science ®Google Scholar
• Antunes LC, Imperi F, Minandri F, et al. In vitro and in vivo antimicrobial activities of gallium nitrate against multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2012;56:5961–5970.
   PubMed Web of Science ®Google Scholar
• Harris TL, Worthington RJ, Hittle LE, et al. Small molecule downregulation of PmrAB reverses lipid A modification and breaks colistin resistance. ACS Chem Biol. 2014;9:122–127.
   PubMed Web of Science ®Google Scholar
• Cebrero-Cangueiro T, Iglesias-Guerra F, Sánchez-Céspedes J, et al. In vitro activity of a library of piperazine derivatives against clinical strains of panresistant Acinetobacter baumannii. 10th International Symposium on the Biology of Acinetobacter 2015. Athens, Greece, p:142.
   Google Scholar
• Cox G, Koteva K, Wright GD. An unusual class of anthracyclines potentiate Gram-positive antibiotics in intrinsically resistant Gram-negative bacteria. J Antimicrob Chemother. 2014;69:1844–1855.
   PubMed Web of Science ®Google Scholar
• Chusri S, Villanueva I, Voravuthikunchai SP, et al. Enhancing antibiotic activity: a strategy to control Acinetobacter infections. J Antimicrob Chemother. 2009;64:1203–1211.
   PubMed Web of Science ®Google Scholar
• Sahu M, Sanjith S, Bhalekar P, et al. War against extended spectrum Beta lactamase and metallobetalactamase producing pathogens- novel adjuvant antimicrobial agent cse1034- an extended hope. J Clin Diagn Res. 2014;8:DC20–DC23.
   PubMedGoogle Scholar
• Chaudhary M, Payasi A. Clinical, microbial efficacy and tolerability of Elores, a novel antibiotic adjuvant entity in ESBL producing pathogens: prospective randomized controlled clinical trial. J Pharm Res. 2013;7:275–280.
   Google Scholar
• Simonetti O, Cirioni O, Ghiselli R, et al. In vitro activity and in vivo animal model efficacy of IB-367 alone and in combination with imipenem and colistin against Gram-negative bacteria. Peptides. 2014;55:17–22.
   PubMed Web of Science ®Google Scholar
• Saugar JM, Rodríguez-Hernández MJ, de la Torre BG, et al. Activity of cecropin A-melittin hybrid peptides against colistin-resistant clinical strains of Acinetobacter baumannii: molecular basis for the differential mechanisms of action. Antimicrob Agents Chemother. 2006;50:1251–1256.
   PubMed Web of Science ®Google Scholar
• Rodríguez-Hernández MJ, Saugar J, Docobo-Pérez F, et al. Studies on the antimicrobial activity of cecropin A-melittin hybrid peptides in colistin-resistant clinical isolates of Acinetobacter baumannii. J Antimicrob Chemother. 2006;58:95–100.
   PubMed Web of Science ®Google Scholar
• López-Rojas R, Docobo-Pérez F, Pachón-Ibáñez ME, et al. Efficacy of cecropin A-melittin peptides on a sepsis model of infection by pan-resistant Acinetobacter baumannii. Eur J Clin Microbiol Infect Dis. 2011;30:1391–1398.
   PubMed Web of Science ®Google Scholar
• Vila-Farrés X, Garcia de la Maria C, López-Rojas R, et al. In vitro activity of several antimicrobial peptides against colistin-susceptible and colistin-resistant Acinetobacter baumannii. Clin Microbiol Infect. 2012;18:383–387.
   PubMed Web of Science ®Google Scholar
• Vila-Farrés X, López-Rojas R, Pachón-Ibáñez ME, et al. Sequence-activity relationship and mechanism of action of mastoparan analogues against extended-drug resistant Acinetobacter baumannii. Eur J Med Chem. 2015;101:34–40.
   PubMed Web of Science ®Google Scholar
• Braunstein A, Papo N, Shai Y. In vitro activity and potency of an intravenously injected antimicrobial peptide and its DL amino acid analog in mice infected with bacteria. Antimicrob Agents Chemother. 2004;48:3127–3129.
   PubMed Web of Science ®Google Scholar
• Huang Y, Wiradharma N, Xu K, et al. Cationic amphiphilic alpha-helical peptides for the treatment of carbapenem-resistant Acinetobacter baumannii infection. Biomaterials. 2012;33:8841–8847.
   PubMed Web of Science ®Google Scholar
• Conlon JM, Ahmed E, Pal T, et al. Potent and rapid bactericidal action of alyteserin-1c and its [E4K] analog against multidrug-resistant strains of Acinetobacter baumannii. Peptides. 2010;31:1806–1810.
   PubMed Web of Science ®Google Scholar
• Xie J, Gou Y, Zhao Q, et al. Antimicrobial activities and membrane-active mechanism of CPF-C1 against multidrug-resistant bacteria, a novel antimicrobial peptide derived from skin secretions of the tetraploid frog Xenopus clivii. J Pept Sci. 2014;20:876–884.
   PubMed Web of Science ®Google Scholar
• Conlon JM, Mechkarska M, Arafat K, et al. Analogues of the frog skin peptide alyteserin-2a with enhanced antimicrobial activities against Gram-negative bacteria. J Pept Sci. 2012b;18:270–275.
   PubMed Web of Science ®Google Scholar
• Conlon JM, Sonnevend A, Pál T, et al. Efficacy of six frog skin-derived antimicrobial peptides against colistin-resistant strains of the Acinetobacter baumannii group. Int J Antimicrob Agents. 2012a;39:317–320.
   PubMed Web of Science ®Google Scholar
• Jiang Z, Vasil AI, Vasil ML, et al. “Specificity Determinants” improve therapeutic indices of two antimicrobial peptides piscidin 1 and dermaseptin s4 against the gram-negative pathogens Acinetobacter baumannii and Pseudomonas aeruginosa. Pharmaceuticals (Basel). 2014;7:366–391.
   PubMedGoogle Scholar
• Conlon JM, Ahmed E, Condamine E. Antimicrobial properties of brevinin-2-related peptide and its analogs: Efficacy against multidrug-resistant Acinetobacter baumannii. Chem Biol Drug Des. 2009;74:488–493.
   PubMed Web of Science ®Google Scholar
• Mangoni ML, Maisetta G, Di Luca M, et al. Comparative analysis of the bactericidal activities of amphibian peptide analogues against multidrug-resistant nosocomial bacterial strains. Antimicrob Agents Chemother. 2008;52:85–91.
   PubMed Web of Science ®Google Scholar
• Parra-Millán R, Jiménez-Mejías ME, Sánchez-Encinales V, et al. Efficacy of lysophosphatidylcholine (LPS) in antimicrobial combined therapy in severe infection murine experimental model. 10th International Symposium on the Biology of Acinetobacter 2015. Athnes, Greece. p:50.
   Google Scholar
• Hicks RP, Abercrombie JJ, Wong RK, et al. Antimicrobial peptides containing unnatural amino acid exhibit potent bactericidal activity against ESKAPE pathogens. Bioorg Med Chem. 2013;21:205–214.
   PubMed Web of Science ®Google Scholar
• Pires J, Siriwardena TN, Stach M, et al. In vitro activity of a novel antimicrobial peptide dendrimer (G3KL) against multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2015;59:7915–7918.
   PubMed Web of Science ®Google Scholar